

# Kimme L Hyrich

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1553502/kimme-l-hyrich-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

175  
papers

7,073  
citations

46  
h-index

79  
g-index

240  
ext. papers

9,175  
ext. citations

4.7  
avg, IF

6.12  
L-index

#	Paper	IF	Citations
175	Juvenile idiopathic arthritis.. <i>Nature Reviews Disease Primers</i> , <b>2022</b> , 8, 5	51.1	7
174	EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology.. <i>Annals of the Rheumatic Diseases</i> , <b>2022</b> ,	2.4	1
173	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry.. <i>RMD Open</i> , <b>2022</b> , 8,	5.9	1
172	Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	21
171	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2129639	10.4	17
170	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology</i> , <b>2021</b> , 3, e855-e864	14.2	11
169	Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	1
168	Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 80	5.7	2
167	Response to: Correspondence on Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry by Mulhearn. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	46
166	Demyelinating Events Following Initiation of Anti-TNF Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2021</b> , 8,	9.1	4
165	Prevalence and predictors of adverse events with methotrexate mono- and combination-therapy for rheumatoid arthritis: a systematic review. <i>Rheumatology</i> , <b>2021</b> , 60, 4001-4017	3.9	5
164	EULAR COVID-19 registry: lessons learnt and future considerations. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1110-1115	2.4	1
163	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1137-1146	2.4	49
162	Response to: Correspondence on Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry by Rosenbaum. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	
161	Common Functional Ability Score for Young People With Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 947-954	4.7	1
160	Translating research into clinical practice: quality improvement to halve non-adherence to methotrexate. <i>Rheumatology</i> , <b>2021</b> , 60, 125-131	3.9	0
159	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 31-35	2.4	61

158	Changes in the illness perceptions of patients with rheumatoid arthritis over the first year of methotrexate therapy. <i>Rheumatology</i> , <b>2021</b> , 60, 2355-2365	3.9	5
157	Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis in the UK: a multicentre prospective longitudinal study. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e111-e121	14.2	5
156	Rheumatic disease and COVID-19: epidemiology and outcomes. <i>Nature Reviews Rheumatology</i> , <b>2021</b> , 17, 71-72	8.1	62
155	Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries. <i>Rheumatology</i> , <b>2021</b> ,	3.9	2
154	Response to: Correspondence on Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry by Arnaud and Devilliers. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	
153	Do people with rheumatoid arthritis maintain their physical activity level at treatment onset over the first year of methotrexate therapy?. <i>Rheumatology</i> , <b>2021</b> , 60, 4633-4642	3.9	2
152	Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics. <i>Scientific Reports</i> , <b>2021</b> , 11, 7266	4.9	5
151	Nothing about us without us: involving patient collaborators for machine learning applications in rheumatology. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1505-1510	2.4	1
150	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	6
149	Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 1800-1809	8.5	2
148	SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	12
147	How effective are JAK-inhibitors? Perspectives from clinical trials and real-world studies. <i>Expert Review of Clinical Immunology</i> , <b>2021</b> , 1-14	5.1	1
146	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. <i>Journal of Rheumatology</i> , <b>2021</b> ,	4.1	3
145	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 930-942	2.4	210
144	Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic Approach. <i>Drugs</i> , <b>2020</b> , 80, 849-857	12.1	10
143	Latent Class Trajectory Modeling of 2-Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic Drugs. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1632-1642	9.5	6
142	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 859-866	2.4	575
141	Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study. <i>Lancet Rheumatology, The</i> , <b>2020</b> , 2, e217-e226	14.2	9

140	Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis. <i>Rheumatology</i> , <b>2020</b> , 59, 2908-2919	3.9	6
139	Cervical screening uptake and rates of cervical dysplasia in the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , <b>2020</b> , 59, 559-567	3.9	1
138	The predictors of and reasons for non-adherence in an observational cohort of patients with rheumatoid arthritis commencing methotrexate. <i>Rheumatology</i> , <b>2020</b> , 59, 213-223	3.9	11
137	Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score. <i>Pharmacogenomics</i> , <b>2020</b> , 21, 1151-1156	2.6	1
136	Long-term outcomes of patients who rate symptoms of rheumatoid arthritis as satisfactory. <i>Rheumatology</i> , <b>2020</b> , 59, 1853-1861	3.9	6
135	What can rheumatology expect from real-world data?. <i>Rheumatology</i> , <b>2020</b> , 59, 12-13	3.9	1
134	Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA. <i>Rheumatology</i> , <b>2020</b> , 59, 1709-1714	3.9	2
133	Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: Comment on Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry by Gianfrancesco. <i>Rheumatology</i> , <b>2020</b> , 59, 1862-1863	2.4	4
132	Harnessing repeated measurements of predictor variables for clinical risk prediction: a review of existing methods. <i>Diagnostic and Prognostic Research</i> , <b>2020</b> , 4, 9	5.5	6
131	COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: Correspondence on Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry by Gianfrancesco. <i>Rheumatology</i> , <b>2020</b> , 59, 1864-1865	2.4	6
130	The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data. <i>Rheumatology</i> , <b>2020</b> , 59, 1391-1397	3.9	6
129	Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis. <i>Rheumatology</i> , <b>2020</b> , 59, 1364-1371	3.9	24
128	Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. <i>Lancet Rheumatology</i> , <b>2020</b> , 2, e250-e253	14.2	125
127	Response to: Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis by Gyöfi. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1000-1001	2.4	7
126	Predicting disease outcomes in juvenile idiopathic arthritis: challenges, evidence, and new directions. <i>The Lancet Child and Adolescent Health</i> , <b>2019</b> , 3, 725-733	14.5	12
125	Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry data. <i>Rheumatology</i> , <b>2019</b> , 58, 1168-1175	3.9	10
124	Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients. <i>Rheumatology</i> , <b>2019</b> , 58, 2162-2169	3.9	17
123	Not all moderate disease is the same - Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity. <i>PLoS ONE</i> , <b>2019</b> , 14, e0215999	3.7	5

122	Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , <b>2019</b> , 58, 1767-1776	3.9	7
121	Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis. <i>Rheumatology</i> , <b>2019</b> ,	3.9	6
120	Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , <b>2019</b> , 58, 80-85	3.9	19
119	Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra. <i>Rheumatology</i> , <b>2019</b> , 58, 94-102	3.9	15
118	A UK study: vocational experiences of young adults with juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , <b>2019</b> , 17, 54	3.5	
117	Real world data in rheumatology. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 49, S22-S24	5.3	1
116	Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?. <i>Current Opinion in Rheumatology</i> , <b>2019</b> , 31, 285-292	5.3	21
115	Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 678-684	9.5	26
114	Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom. <i>Rheumatology</i> , <b>2019</b> , 58, 331-335	3.9	13
113	Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , <b>2018</b> , 57, 997-1001	3.9	57
112	Long-Term Outcomes Following Achievement of Clinically Inactive Disease in Juvenile Idiopathic Arthritis: The Importance of Definition. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 1519-1529	9.5	16
111	The relationship between depression and biologic treatment response in rheumatoid arthritis: An analysis of the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , <b>2018</b> , 57, 835-843	3.9	54
110	Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register. <i>RMD Open</i> , <b>2018</b> , 4, e000596	5.9	26
109	The influence of TNF inhibitors on dementia incidence in patients with rheumatoid arthritis; an analysis from the BSRBR-RA. <i>International Journal of Geriatric Psychiatry</i> , <b>2018</b> , 33, 556-558	3.9	7
108	2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 476-479	2.4	45
107	Depressive symptoms, pain and disability for adolescent patients with juvenile idiopathic arthritis: results from the Childhood Arthritis Prospective Study. <i>Rheumatology</i> , <b>2018</b> , 57, 1381-1389	3.9	28
106	Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 905-910	2.4	83
105	Long-term persistence with rituximab in patients with rheumatoid arthritis. <i>Rheumatology</i> , <b>2018</b> , 57, 1089-1096	3.9	17

104	The prioritization of symptom beliefs over illness beliefs: The development and validation of the Pain Perception Questionnaire for Young People. <i>British Journal of Health Psychology</i> , <b>2018</b> , 23, 68-87	8.3	8
103	Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1405-1412	2.4	63
102	Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). <i>Arthritis Research and Therapy</i> , <b>2018</b> , 20, 147	5.7	36
101	Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , <b>2018</b> , 57, 1533-1540	3.9	15
100	Patterns of pain over time among children with juvenile idiopathic arthritis. <i>Archives of Disease in Childhood</i> , <b>2018</b> , 103, 437-443	2.2	27
99	Growth patterns in early juvenile idiopathic arthritis: Results from the Childhood Arthritis Prospective Study (CAPS). <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 48, 53-60	5.3	16
98	Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2018</b> , 32, 869-886	5.3	33
97	Update on the epidemiology, risk factors and disease outcomes of Juvenile idiopathic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2018</b> , 32, 206-222	5.3	24
96	Prevalence and course of lower limb disease activity and walking disability over the first 5 years of juvenile idiopathic arthritis: results from the childhood arthritis prospective study. <i>Rheumatology Advances in Practice</i> , <b>2018</b> , 2, rky039	1.1	6
95	Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1705-1709	2.4	45
94	Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , <b>2018</b> , 18, 657-664	3.5	32
93	Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 654-660	2.4	82
92	High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 208-213	2.4	40
91	Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 386-391	2.4	105
90	Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 497-503	2.4	63
89	Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. <i>RMD Open</i> , <b>2017</b> , 3, e000314	5.9	21
88	How common is clinically inactive disease in a prospective cohort of patients with juvenile idiopathic arthritis? The importance of definition. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1381-1388	2.4	27
87	Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 241-250	3.9	23

86	How common is remission in juvenile idiopathic arthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2017</b> , 47, 331-337	5.3	32
85	Biologics registers in RA: methodological aspects, current role and future applications. <i>Nature Reviews Rheumatology</i> , <b>2017</b> , 13, 503-510	8.1	37
84	Mortality rates are increased in patients with systemic juvenile idiopathic arthritis. <i>Archives of Disease in Childhood</i> , <b>2017</b> , 102, 206-207	2.2	9
83	The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort. <i>Rheumatology</i> , <b>2017</b> , 56, 1019-1024	3.9	7
82	Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 2025-2030	2.4	46
81	A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities. <i>Pediatric Rheumatology</i> , <b>2017</b> , 15, 31	3.5	17
80	Pregnancy outcomes in women with rheumatoid arthritis ever treated with rituximab. <i>Rheumatology</i> , <b>2017</b> , 56, 661-663	3.9	4
79	Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2017</b> , 46, 584-593	5.3	23
78	Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti-Tumor Necrosis Factor. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 783-793	4.7	25
77	Response to: Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor? by Nocturne et al. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, e4	2.4	2
76	Does sex or ethnicity impact anti-tumour necrosis factor agent use in rheumatoid arthritis?. <i>Rheumatology</i> , <b>2017</b> , 56, 663-665	3.9	
75	Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. <i>Rheumatology</i> , <b>2016</b> , 55, 2050-2055	3.9	10
74	Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 251	5.7	114
73	What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 282	5.7	12
72	Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS). <i>Seminars in Arthritis and Rheumatism</i> , <b>2016</b> , 46, 190-195	5.3	18
71	Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 715-20	2.6	8
70	Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers. <i>Rheumatology</i> , <b>2016</b> , 55, 1556-65	3.9	29
69	Influence of past breast feeding on pattern and severity of presentation of juvenile idiopathic arthritis. <i>Archives of Disease in Childhood</i> , <b>2016</b> , 101, 348-51	2.2	19

68	Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis. <i>RMD Open</i> , <b>2016</b> , 2, e000273	5.9	5
67	Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes. <i>RMD Open</i> , <b>2016</b> , 2, e000171	5.9	26
66	Trends in paediatric rheumatology referral times and disease activity indices over a ten-year period among children and young people with Juvenile Idiopathic Arthritis: results from the childhood arthritis prospective Study. <i>Rheumatology</i> , <b>2016</b> , 55, 1225-34	3.9	37
65	Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. <i>Rheumatology</i> , <b>2016</b> , 55, 840-7	3.9	23
64	Risk of <i>Pneumocystis jirovecii</i> pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor – results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , <b>2016</b> , 55, 1336-7	3.9	10
63	The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. <i>Rheumatology</i> , <b>2016</b> , 55, 2033-2039	3.9	45
62	Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1337-45	9.5	11
61	Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1353-60	9.5	46
60	Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. <i>Rheumatology</i> , <b>2015</b> , 54, 494-9	3.9	69
59	Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1645-56	27.4	92
58	Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1087-93	2.4	102
57	Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. <i>Lancet, The</i> , <b>2015</b> , 385 Suppl 1, S48 <sup>40</sup>		12
56	Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. <i>Rheumatology</i> , <b>2015</b> , 54, 1279-85	3.9	11
55	The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. <i>Rheumatology</i> , <b>2015</b> , 54, 1780-91	3.9	55
54	Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 2487-94	9.5	40
53	Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 359	5.7	5
52	Consistency and Utility of Data Items Across European Rheumatoid Arthritis Clinical Cohorts and Registers. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 1219-1229	4.7	11
51	PP3. Standardized mortality rates are increased in patients with severe JIA. <i>Rheumatology</i> , <b>2015</b> , 54, ii6-ii6	3.9	2

50	The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. <i>Rheumatology</i> , <b>2015</b> , 54, 1074-1079	3.9	19
49	The association between low socioeconomic status with high physical limitations and low illness self-perception in patients with juvenile idiopathic arthritis: results from the Childhood Arthritis Prospective Study. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 382-9	4.7	16
48	HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 15970-5	11.5	103
47	Biologic therapies and pregnancy: the story so far. <i>Rheumatology</i> , <b>2014</b> , 53, 1377-85	3.9	80
46	Rheumatoid arthritis: When TNF inhibitors fail in RA--weighing up the options. <i>Nature Reviews Rheumatology</i> , <b>2014</b> , 10, 262-4	8.1	5
45	P2. Incidence and Severity of Myocardial Infarction in Subjects Receiving Anti-Tumour Necrosis Factor Drugs for Rheumatoid Arthritis: Results from Linking the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and Myocardial Ischaemia National Audit Project. <i>Rheumatology</i> , <b>2014</b> , 53, i37-i38	3.9	4
44	O23. The Influence of Anti-TNF or Rituximab on Cancer Incidence in Patients with Rheumatoid Arthritis who Have Had a Prior Malignancy. <i>Rheumatology</i> , <b>2014</b> , 53, i38-i38	3.9	
43	Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 229-34	2.4	128
42	Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. <i>Rheumatology</i> , <b>2013</b> , 52, 91-8	3.9	90
41	Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. <i>PLoS Genetics</i> , <b>2013</b> , 9, e1003394	6	127
40	Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 143-4	2.4	24
39	Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , <b>2013</b> , 52, 1905-13	3.9	22
38	Recent developments in disease activity indices and outcome measures for juvenile idiopathic arthritis. <i>Rheumatology</i> , <b>2013</b> , 52, 1941-51	3.9	20
37	Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1983-8	2.4	85
36	The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1315-20	2.4	90
35	Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UK. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 461-2	2.4	24
34	Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 1108-15	4.7	69
33	Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 240-6	4.1	54

32	Abatacept in the long-term treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , <b>2012</b> , 8, 231-4	5.1	4
31	Juvenile-onset inflammatory arthritis: a study of adolescents' beliefs about underlying cause. <i>Rheumatology</i> , <b>2012</b> , 51, 2239-45	3.9	3
30	Prediction of response and adverse events to methotrexate treatment in patients with rheumatoid arthritis. <i>International Journal of Clinical Rheumatology</i> , <b>2012</b> , 7, 559-567	1.5	3
29	The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 869-74	2.4	87
28	Agreement between proxy and adolescent assessment of disability, pain, and well-being in juvenile idiopathic arthritis. <i>Journal of Pediatrics</i> , <b>2011</b> , 158, 307-12	3.6	27
27	Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 645-53		124
26	Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. <i>Rheumatology</i> , <b>2011</b> , 50, 124-31	3.9	463
25	Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 583-9	2.4	155
24	Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 823-6	2.4	131
23	Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. <i>Rheumatology</i> , <b>2011</b> , 50, 117-23	3.9	66
22	Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. <i>Rheumatology</i> , <b>2011</b> , 50, 189-95	3.9	54
21	Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 1831-4	2.4	46
20	Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers. <i>Rheumatology</i> , <b>2011</b> , 50, 146-51	3.9	16
19	BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. <i>Rheumatology</i> , <b>2010</b> , 49, 1197-9	3.9	44
18	Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to paediatric rheumatology. Results from the Childhood Arthritis Prospective Study. <i>Rheumatology</i> , <b>2010</b> , 49, 116-22	3.9	73
17	Comment on: Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register: reply. <i>Rheumatology</i> , <b>2010</b> , 49, 1794-1794 <sup>3.9</sup>		
16	Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , <b>2010</b> , 49, 697-705	3.9	91
15	BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. <i>Rheumatology</i> , <b>2010</b> , 49, 2217-9	3.9	166

14	Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , <b>2010</b> , 49, 1570-7	3.9	52
13	Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 1849-61		74
12	No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 3145-53		58
11	Different methods of balancing covariates leading to different effect estimates in the presence of effect modification. <i>American Journal of Epidemiology</i> , <b>2009</b> , 169, 909-17	3.8	59
10	Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. <i>Rheumatology</i> , <b>2009</b> , 48, 1323-7	3.9	44
9	Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. <i>BioDrugs</i> , <b>2009</b> , 23, 111-24	7.9	58
8	Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. <i>Arthritis Research and Therapy</i> , <b>2009</b> , 11, R52	5.7	138
7	Patients with suspected rheumatoid arthritis should be referred early to rheumatology. <i>BMJ, The</i> , <b>2008</b> , 336, 215-6	5.9	18
6	Are patients with RA at increased risk of malignancy?. <i>Nature Clinical Practice Rheumatology</i> , <b>2008</b> , 4, 632-3		
5	Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. <i>Rheumatology</i> , <b>2008</b> , 47, 1000-5	3.9	61
4	Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 13-20		328
3	Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 54, 1701-9		114
2	Assessing the safety of biologic therapies in rheumatoid arthritis: the challenges of study design. <i>Journal of rheumatology Supplement, The</i> , <b>2005</b> , 72, 48-50		7
1	The role of the British Society for Rheumatology Biologics Register (BSRBR) and the NICE guidelines for anti-TNF therapy. <i>Musculoskeletal Care</i> , <b>2003</b> , 1, 58-64	1.6	9